Solid Biosciences (SLDB) Capital Expenditures (2017 - 2026)
Solid Biosciences (SLDB) reported Capital Expenditures of $165000.0 for Q1 2026, up 30.95% on a YoY basis from $126000.0 in Q1 2025, and up 130.44% sequentially from -$542000.0 in Q4 2025.
Solid Biosciences (SLDB) Capital Expenditures (2017 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 10 years of Capital Expenditures data on file, last reported at $165000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 30.95% year-over-year to $165000.0; the trailing twelve-month figure through Mar 2026 stood at $85000.0 (down 86.53% YoY), and the FY2025 full-year result was $46000.0, down 92.97% from the prior year.
- Capital Expenditures improved to $165000.0 in Q1 2026, from -$542000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2023 to a low of -$1.1 million in Q3 2022.
- A 5-year average of $171000.0 and a median of $165000.0 in 2026 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 1740.0% in 2022, while the deepest fall reached 2728.21% in 2022.
- Tracing SLDB's Capital Expenditures over 5 years: stood at $310000.0 in 2022, then surged by 388.71% to $1.5 million in 2023, then sank by 59.21% to $618000.0 in 2024, then tumbled by 187.7% to -$542000.0 in 2025, then surged by 130.44% to $165000.0 in 2026.
- Business Quant data shows SLDB's Capital Expenditures at $165000.0 in Q1 2026, -$542000.0 in Q4 2025, and $588000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Solid Biosciences | 871.35 Mn | 871.35 Mn | - | 165,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,000.00 |
| Mar 31, 2026 | 165,000.00 |
| Dec 31, 2025 | -542,000.00 |
| Dec 31, 2025 | -542,000.00 |
| Sep 30, 2025 | 588,000.00 |
| Sep 30, 2025 | 588,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Mar 31, 2025 | 126,000.00 |
| Mar 31, 2025 | 126,000.00 |
| Dec 31, 2024 | 618,000.00 |
| Dec 31, 2024 | 618,000.00 |
| Sep 30, 2024 | -399,000.00 |
| Sep 30, 2024 | -399,000.00 |
| Jun 30, 2024 | 286,000.00 |
| Jun 30, 2024 | 286,000.00 |
| Mar 31, 2024 | 149,000.00 |
| Mar 31, 2024 | 149,000.00 |
| Dec 31, 2023 | 1.52 Mn |
| Dec 31, 2023 | 1.52 Mn |